| Name | Title | Contact Details |
|---|
The Victorian Department of Health & Human Services develops and delivers policies, programs and services that support and enhance the wellbeing of all Victorians.
An individualized, trauma-sensitive, and holistic approach to addressing boys` emotional and behavioral issues, and educational, recreational, and vocational goals.
Par Pharmaceutical Companies, Inc. is a holding company that, principally through its wholly owned subsidiary, Par Pharmaceutical, Inc., is in the business of developing, manufacturing and distributing generic and branded drugs in the United States.
Ambient Clinical Analytics is the creator of a software platform designed for data assimilation, communication and analytics. It is based on decision support tools initially deployed in the intensive care unit (ICU) or emergency department of hospitals. Our software consists of algorithms that mine data from electronic medical records (EMR). It then presents that data to the physicians and nurses so they may facilitate real-time clinical decision making and care delivery. These products are positioned as add on applications that are designed to easily integrate with the current major EMR providers. The highly fragmented global Healthcare IT and EMR market is expected to grow by 15% to $10 billion by 2015. Ambient believes there is a significant opportunity in this growing market to implement analytics based dashboard tools to reduce errors and improve efficiency. Our goal is supported by a $16 million CMS grant to deploy Ambient’s AWARE program in 3 hospitals starting September 2013. This software platform can be used in any data intensive hospital unit and is the perfect combination of “Big Data” and “Analytics”. Our analytical tools and suggested care checklists are unique to the current healthcare IT market. Ambient Clinical Analytics is supported financially by software license fees, SaaS, Cloud, and system integration revenue.
Acucela is a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of sight-threatening ophthalmic diseases impacting millions of individuals worldwide. Acucela currently has the following candidates in development with Otsuka Pharmaceutical: emixustat hydrochloride for GA associated with dry AMD based on Acucela’s proprietary visual cycle modulation; and OPA-6566 for ocular hypertension and glaucoma.